Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Colitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Colitis - Pipeline Review, H1 2015', provides an overview of the Colitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Colitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Colitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Colitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Colitis Overview 8 Therapeutics Development 9 Pipeline Products for Colitis - Overview 9 Pipeline Products for Colitis - Comparative Analysis 10 Colitis - Therapeutics under Development by Companies 11 Colitis - Therapeutics under Investigation by Universities/Institutes 13 Colitis - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Colitis - Products under Development by Companies 16 Colitis - Products under Investigation by Universities/Institutes 17 Colitis - Companies Involved in Therapeutics Development 18 Ajinomoto Pharmaceuticals Co., Ltd. 18 Akebia Therapeutics, Inc. 19 BioLineRx, Ltd. 20 Cognosci, Inc. 21 Galapagos NV 22 GeneFrontier Corporation 23 Inovio Pharmaceuticals, Inc. 24 N30 Pharmaceuticals 25 Prokarium Ltd. 26 Protalix BioTherapeutics, Inc. 27 Synovo GmbH 28 Colitis - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 AcTMP-1 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 AKB-6899 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 APY-0201 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 BC-1215 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 BL-5040 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 C-142 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 clostridium difficile vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 COG-112 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 CSY-0073 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 etanercept biosimilar - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 filgotinib - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 GFC-101 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 N-6022 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 N-6547 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 NK-007 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 RNAi Oligonucleotides to Inhibit TNFalpha for IBD and Colitis - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecule for Colitis - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Synthetic Peptides to Inhibit Panx1 for Colitis - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Vaccine for Colitis - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Vaccine to Target Interleukin-23 for Colitis - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 VGX-1027 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Colitis - Recent Pipeline Updates 63 Colitis - Dormant Projects 70 Appendix 73 Methodology 73 Coverage 73 Secondary Research 73 Primary Research 73 Expert Panel Validation 73 Contact Us 73 Disclaimer 74
List of Tables Number of Products under Development for Colitis, H1 2015 9 Number of Products under Development for Colitis - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Colitis - Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2015 18 Colitis - Pipeline by Akebia Therapeutics, Inc., H1 2015 19 Colitis - Pipeline by BioLineRx, Ltd., H1 2015 20 Colitis - Pipeline by Cognosci, Inc., H1 2015 21 Colitis - Pipeline by Galapagos NV, H1 2015 22 Colitis - Pipeline by GeneFrontier Corporation, H1 2015 23 Colitis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 24 Colitis - Pipeline by N30 Pharmaceuticals, H1 2015 25 Colitis - Pipeline by Prokarium Ltd., H1 2015 26 Colitis - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 27 Colitis - Pipeline by Synovo GmbH, H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Number of Products by Stage and Target, H1 2015 31 Number of Products by Stage and Mechanism of Action, H1 2015 33 Number of Products by Stage and Route of Administration, H1 2015 35 Number of Products by Stage and Molecule Type, H1 2015 37 Colitis Therapeutics - Recent Pipeline Updates, H1 2015 63 Colitis - Dormant Projects, H1 2015 70 Colitis - Dormant Projects (Contd..1), H1 2015 71 Colitis - Dormant Projects (Contd..2), H1 2015 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
